Beta Bionics

United States
Glenwood City, Wisconsin, United States, 92618

Company profile

Beta Bionics company profile

Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.

Business identity

Contact email
[email protected]
Phone number
909-800-3351
Operating status
Active
Company type
For Profit
Employee range
251-500 employees
Revenue range
$1M-$10M
Founded
2015-10-21

Headquarters

Postal code
92618
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
9
Total equity funding
$351.5M
Last funding
Series E / $60M / 2024-11-13
Last equity funding
Series E / $60M
Investors
17
Lead investors
11
Founders
4
Articles
152
Exited on
2025-01-30

Founders and investors

Founders

Ed DamianoEdward RaskinSean SaintToby Milgrome

Lead investors

Eli LillyEventideFarallon Capital ManagementNational Institute of Diabetes and Digestive and Kidney DiseasesNovo NordiskOmega FundsPerceptive AdvisorsRTW InvestmentsSands Capital VenturesSoleus Capital

Investors

Eli LillyNovo NordiskOmega FundsRTW InvestmentsWellington Management